US20210121525A1 - Silk fibroin-containing composition and methods of use thereof - Google Patents
Silk fibroin-containing composition and methods of use thereof Download PDFInfo
- Publication number
- US20210121525A1 US20210121525A1 US16/757,195 US201816757195A US2021121525A1 US 20210121525 A1 US20210121525 A1 US 20210121525A1 US 201816757195 A US201816757195 A US 201816757195A US 2021121525 A1 US2021121525 A1 US 2021121525A1
- Authority
- US
- United States
- Prior art keywords
- surfactant
- silk fibroin
- certain embodiments
- composition
- perfluorocarbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010022355 Fibroins Proteins 0.000 title claims abstract description 320
- 239000000203 mixture Substances 0.000 title claims abstract description 127
- 238000000034 method Methods 0.000 title claims abstract description 51
- 239000004094 surface-active agent Substances 0.000 claims abstract description 271
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims abstract description 153
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract description 61
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract description 60
- 208000019693 Lung disease Diseases 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 18
- 230000007812 deficiency Effects 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 229960005486 vaccine Drugs 0.000 claims abstract description 15
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 claims description 67
- 229960001217 perflubron Drugs 0.000 claims description 66
- 239000007788 liquid Substances 0.000 claims description 62
- 210000004072 lung Anatomy 0.000 claims description 58
- 238000009423 ventilation Methods 0.000 claims description 42
- 102000004190 Enzymes Human genes 0.000 claims description 23
- 108090000790 Enzymes Proteins 0.000 claims description 23
- 235000008979 vitamin B4 Nutrition 0.000 claims description 20
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 19
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 19
- -1 polyoxyethylenes Polymers 0.000 claims description 17
- 239000003937 drug carrier Substances 0.000 claims description 15
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 14
- 201000004193 respiratory failure Diseases 0.000 claims description 14
- HQKASRVURLHPOF-UHFFFAOYSA-N 1,1,2,2,3,3,3a,4,4,5,5,6,6,7,7,8,8,8a-octadecafluoroazulene Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)C(F)(F)C(F)(F)C2(F)F HQKASRVURLHPOF-UHFFFAOYSA-N 0.000 claims description 11
- LWRNQOBXRHWPGE-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8a-heptadecafluoro-8-(trifluoromethyl)naphthalene Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(C(F)(F)F)(F)C(F)(F)C(F)(F)C(F)(F)C21F LWRNQOBXRHWPGE-UHFFFAOYSA-N 0.000 claims description 11
- NZXAVWBNLOQPGY-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-hexadecafluoro-4a,8a-bis(trifluoromethyl)naphthalene Chemical compound FC(F)(F)C12C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C2(F)F NZXAVWBNLOQPGY-UHFFFAOYSA-N 0.000 claims description 11
- TVVLGUNBMNTDPU-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,6,6,7,7,8,8,9,9,9a-heptadecafluoroquinolizine Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)N21 TVVLGUNBMNTDPU-UHFFFAOYSA-N 0.000 claims description 11
- BOEIBTHDYSPVLT-UHFFFAOYSA-N 1,1-dichloro-1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hexadecafluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(Cl)Cl BOEIBTHDYSPVLT-UHFFFAOYSA-N 0.000 claims description 11
- XLHQMWKXRIHHSX-UHFFFAOYSA-N 1,1-dichloro-4-(4,4-dichloro-1,1,2,2,3,3,4-heptafluorobutoxy)-1,2,2,3,3,4,4-heptafluorobutane Chemical compound FC(Cl)(Cl)C(F)(F)C(F)(F)C(F)(F)OC(F)(F)C(F)(F)C(F)(F)C(F)(Cl)Cl XLHQMWKXRIHHSX-UHFFFAOYSA-N 0.000 claims description 11
- SCPDYEAXXZZBIC-UHFFFAOYSA-N FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)N(C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C21F Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)N(C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C21F SCPDYEAXXZZBIC-UHFFFAOYSA-N 0.000 claims description 11
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims description 11
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims description 11
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims description 11
- 229950011087 perflunafene Drugs 0.000 claims description 11
- LRMQIJUOLGKFKS-UHFFFAOYSA-N perfluoro-1,3-dimethyladamantane Chemical compound FC1(F)C(C2(F)F)(F)C(F)(F)C3(F)C(F)(F)C1(C(F)(F)F)C(F)(F)C2(C(F)(F)F)C3(F)F LRMQIJUOLGKFKS-UHFFFAOYSA-N 0.000 claims description 11
- FYJQJMIEZVMYSD-UHFFFAOYSA-N perfluoro-2-butyltetrahydrofuran Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)OC(F)(F)C(F)(F)C1(F)F FYJQJMIEZVMYSD-UHFFFAOYSA-N 0.000 claims description 11
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 claims description 11
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- 229940026290 calfactant Drugs 0.000 claims description 10
- 229940068998 egg yolk phospholipid Drugs 0.000 claims description 10
- 239000008344 egg yolk phospholipid Substances 0.000 claims description 10
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 10
- 239000012736 aqueous medium Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 8
- 208000000203 Hyaline Membrane Disease Diseases 0.000 claims description 8
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 8
- 208000007123 Pulmonary Atelectasis Diseases 0.000 claims description 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 38
- 239000007864 aqueous solution Substances 0.000 description 32
- 239000003580 lung surfactant Substances 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 20
- 102000016911 Deoxyribonucleases Human genes 0.000 description 18
- 108010053770 Deoxyribonucleases Proteins 0.000 description 18
- 239000007789 gas Substances 0.000 description 17
- 239000006185 dispersion Substances 0.000 description 12
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000002934 diuretic Substances 0.000 description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 10
- 150000003431 steroids Chemical class 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000001882 diuretic effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000255789 Bombyx mori Species 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- XRPFBSTYXSIGNA-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br.FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br XRPFBSTYXSIGNA-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 235000021314 Palmitic acid Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 229940066294 lung surfactant Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 229940026289 infasurf Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005399 mechanical ventilation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 101710197767 Fibroin heavy chain Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 description 2
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 2
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 description 2
- 108010013296 Sericins Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 229960001947 tripalmitin Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- COQIQRBKEGPRSG-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoro-2-(trifluoromethyl)propane Chemical compound FC(F)(F)C(F)(C(F)(F)F)C(F)(F)F COQIQRBKEGPRSG-UHFFFAOYSA-N 0.000 description 1
- PAZGBAOHGQRCBP-ZCXUNETKSA-N 1-Palmitoyl-2-oleoylglycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-ZCXUNETKSA-N 0.000 description 1
- PAZGBAOHGQRCBP-HGWHEPCSSA-N 1-hexadecanoyl-2-[(9Z)-octadec-9-enoyl]-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-HGWHEPCSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 101100060007 Caenorhabditis elegans mig-22 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000006079 Near drowning Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 108010031254 Venticute Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940066363 beractant Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003479 colfosceril palmitate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940092456 curosurf Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 108010015964 lucinactant Proteins 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- GUKVIRCHWVCSIZ-ROKJYLDNSA-N lusupultide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)[C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C1=CN=CN1 GUKVIRCHWVCSIZ-ROKJYLDNSA-N 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical group OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 229940080796 surfaxin Drugs 0.000 description 1
- 229940063649 survanta Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0082—Lung surfactant, artificial mucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- Liquid silk is produced by a variety of insects and spiders.
- the best characterized silks are cocoon silk from the domesticated silkworm Bombyx mori.
- Bombyx mori silk is composed of a core protein, silk fibroin, and a glue-like coating consisting of a nonfilamentous protein, sericin.
- the core protein of Bombyx mori silk is made from two structural proteins, fibroin heavy chain ( ⁇ 325 kDa) and light chain ( ⁇ 25 kDa).
- the fibroin heavy chain protein consists of layers of antiparallel beta sheets, and its primary structure mainly consists of the recurrent hydrophobic amino acid sequence Gly-Ser-Gly-Ala-Gly-Ala (GSGAGA) (SEQ ID NO:1).
- Silk fibroin is a natural or synthetic polymer used in textile production, medical sutures, and more recently as a scaffold for tissue regeneration and other medical applications.
- perfluorochemicals have been proposed for use as perfusates for organs, as blood substitutes, and as liquids for liquid lavaging or liquid ventilation of the lungs.
- Perfluorocarbons PFCs
- PFCs Perfluorocarbons
- rats have been shown to survive total immersion in a liquid perfluorochemical saturated with oxygen.
- the high solubility of oxygen in most perfluorochemicals enables the rat to “breathe” the perfluorochemical. This process, and its variants, are commonly referred to as liquid ventilation.
- perfluorochemical assisted gas exchange a pure fluorochemical liquid is instilled into the lungs of an animal in an amount equal to the functional residual capacity of the lungs. The animal then is connected to a mechanical ventilator which delivers tidal volumes of a breathable gas to the lungs.
- PAGE perfluorochemical assisted gas exchange
- the PAGE technique is extremely limited with respect to the ability to deliver drugs to the lungs. Because perfluorochemicals are both hydrophobic and lipophobic, very few medicaments other than halocarbon anesthetics may be delivered to the lungs using such liquid breathing techniques.
- RDS respiratory distress syndrome
- exogenous surfactant is not uniformly effective in treating preterm infants with RDS because the surfactant fails to reach atelectatic alveoli.
- Perfluorocarbons have been shown to be effective in recruiting atelectatic areas but do not replace impaired endogenous surfactant.
- An aspect of the invention is a composition comprising silk fibroin and a perfluorocarbon.
- the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-o
- An aspect of the invention is a composition comprising silk fibroin and a surfactant.
- the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof.
- the surfactant is not a perfluorocarbon.
- An aspect of the invention is a composition comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-
- the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- any one of the foregoing compositions further comprises a drug, enzyme, antibody, or vaccine.
- An aspect of the invention is a method of making any one of the foregoing compositions.
- An aspect of the invention is a method of treating a lung disease or lung condition, comprising administering a therapeutically effective amount of any one of the aforementioned compositions to an airway of a subject in need thereof.
- the subject is a human.
- the subject is a preterm infant.
- the subject is an infant.
- the lung disease or lung condition is selected from the group consisting of respiratory failure, surfactant deficiency, respiratory distress syndrome (RDS), adult respiratory distress syndrome (ARDS), meconium aspiration syndrome, hyaline membrane disease, pneumonia, cystic fibrosis, idiopathic pulmonary fibrosis, atelectasis, and any combination thereof.
- the lung disease or lung condition is respiratory distress syndrome (RDS).
- the administering comprises liquid ventilation.
- the administering comprises lung lavage, e.g., bronchoalveolar lavage (BAL).
- An aspect of the invention is a kit comprising components of any one of the aforementioned compositions.
- FIG. 1A is a photographic image depicting an aqueous mixture of silk fibroin and PFC (perfluorooctylbromide).
- FIG. 1B is a photographic image depicting an aqueous mixture of silk fibroin and surfactant.
- FIG. 1C is a photographic image depicting an aqueous mixture of PFC and surfactant.
- FIG. 1D is a photographic image depicting an aqueous mixture of silk fibroin, surfactant, and PFC prior to vigorous shaking.
- FIG. 1E is a photographic image depicting an aqueous mixture of silk fibroin, surfactant, and PFC after vigorous shaking.
- compositions of the invention include aqueous mixtures of silk fibroin and (a) perfluorocarbon, (b) surfactant, or (c) both perfluorocarbon and surfactant.
- aqueous mixtures of silk fibroin and (a) perfluorocarbon, (b) surfactant, or (c) both perfluorocarbon and surfactant are deemed to be an active agent.
- the compositions or mixtures of the invention can further comprise one or more additional agents, including other active pharmaceutical ingredients (APIs).
- APIs active pharmaceutical ingredients
- the compositions of the invention are believed to be useful in the treatment of certain lung diseases and lung conditions, including ARDS.
- the silk fibroin component is believed to facilitate the delivery, and therefore enhance the efficacy, of each component with which it is combined in accordance with the compositions of the invention.
- the combination of silk fibroin, perfluorocarbon, and surfactant exhibits synergistic biological properties over any pair of these three components.
- the aqueous mixtures are dispersions. In certain embodiments, the aqueous mixtures are emulsions. In certain embodiments, the aqueous mixtures are microemulsions. As will be discussed below, the various components can be combined in various relative amounts or ratios.
- a “silk fibroin” or “fibroin” refers to natural or recombinant silk fibroin.
- the silk fibroin is derived from the domesticated Bombyx mori silkworm.
- “silk fibroin” refers to an aqueous solution containing natural or recombinant silk fibroin protein. See, for example, U.S. Pat. No. 7,635,755, International Patent Application Publication No. WO 97/08315, and U.S. Pat. No. 5,245,012, the entire contents of which are incorporated herein by reference.
- Silk is a well described natural fiber produced by the silkworm, Bombyx mori , which has been used traditionally in the form of threads in textiles for thousands of years.
- This silk contains a fibrous protein termed fibroin (both heavy and light chains) that form the thread core, and glue-like proteins termed sericin that surround the fibroin fibers to cement them together.
- the fibroin is a highly insoluble protein containing up to 90% the amino acids glycine, alanine and serine leading to ⁇ -pleated sheet formation in the fibers (Asakura, et al., Encyclopedia of Agricultural Science , Arntzen, C. J., Ritter, E. M. Eds.; Academic Press: New York, N.Y., 1994; Vol. 4, pp 1-11).
- Silk fibroin has been proposed as a vehicle for drug delivery. See, for example, Wenk et al. Biomaterials 31: 1403-13 (2010), and Wenk et al. J Control Release 150: 128-41 (2011), the entire contents of which are incorporated herein by reference.
- Silk fibroin has unique self-assembly process (driving force: hydrophobicity and electrostatic interactions), and it acts like a cocoon for biological matter. Cells show normal growth and proliferation in the presence of silk fibroin.
- a common and straightforward way to incorporate drugs into the fabrication of silk fibroin delivery system is by dissolving or mixing them directly into silk fibroin solution. Addition of enzymes or antibodies or vaccines to liquid silk solution (the self-assembly process) preserves the biological function of these compounds.
- the silk fibroin is provided as a commercial product, for example, silk fibroin 50 mg/mL in aqueous solution (Sigma-Aldrich).
- a “perfluorocarbon” or “PFC” refers to a hydrocarbon, or optionally a substituted hydrocarbon, in which all C—H bonds have been replaced by C—F bonds.
- Perfluorocarbons include perfluoroalkanes, perfluoroalkenes, perfluoroalkynes, and perfluoroaromatic compounds.
- a “perfluorocarbon” refers to a perfluoroalkane.
- the alkane portion can be unbranched, branched, or cyclical.
- perfluoroalkane gases There are five perfluoroalkane gases: tetrafluoromethane (bp ⁇ 128° C.), hexafluoroethane (bp ⁇ 78.2° C.), octafluoropropane (bp ⁇ 36.5° C.), perfluoro-n-butane (bp ⁇ 2.2° C.), and perfluoro-iso-butane (bp ⁇ 1° C.). Nearly all other fluoroalkanes are liquids.
- PFC liquids have low surface tension and at atmospheric pressure, large amounts of oxygen and carbon dioxide dissolve in them. For example, PFC carries 20 times more oxygen than saline/water and twice that of blood. The 02 diffusion rate from PFC-filled alveoli to the alveolar capillaries is quite high. Clear, colorless, odorless, non-conducting, and non-flammable, PFCs are insoluble in water and only sparingly soluble in lipid. PFCs are not metabolized in body tissues.
- a perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- a perfluorocarbon may be presented in a gas or liquid form.
- Liquid forms may include a water-in-perfluorocarbon stable liquid dispersion or a perfluorocarbon-in-water microemulsion.
- Homogenous water-in-perfluorochemical stable liquid dispersions are disclosed in U.S. Pat. No. 5,770,585, the entire content of which is incorporated herein by reference.
- a perfluorocarbon is provided as a commercial product, for example, LiquiVent® (perfluorooctylbromide; perflubron; Origen Biomedical, Austin, Tex.).
- a “surfactant” refers to a compound that lowers the surface tension between two liquids or between a liquid and a solid.
- a surfactant is a pulmonary surfactant.
- Pulmonary surfactant is a surface-active phospholipoprotein complex formed by type II alveolar cells of the lung.
- the proteins and lipids that make up the surfactant have both hydrophilic and hydrophobic regions.
- DPPC dipalmitoylphosphatidylcholine
- Pulmonary surfactant increases pulmonary compliance and facilitates recruitment of collapsed (atelectatic) airways.
- Most preterm infants are surfactant-deficient at birth and as a result have respiratory problems, including respiratory distress syndrome (RDS).
- RDS respiratory distress syndrome
- Pulmonary surfactants generally include synthetic pulmonary surfactants and animal-derived pulmonary surfactants. Both synthetic pulmonary surfactants and animal-derived pulmonary surfactants are useful in the invention.
- Synthetic pulmonary surfactants include, without limitation, colfosceril palmitate (Exosurf), a mixture of dipalmitoylphosphatidylcholine (DPPC) with hexadecanol and tyloxapol; pumactant, a mixture of DPPC and phosphatidylglycerol (PG); KL-4, a mixture of DPPC, palmitoyl-oleoyl phosphatidylglycerol, and palmitic acid, combined with a 21 amino acid synthetic peptide that mimics the structural characteristics of surfactant protein B (SP-B); venticute, a mixture of DPPC, PG, palmitic acid, and recombinant surfactant protein C (SP-C); and lucinactant (Surfaxin), a mixture of KL4 acetate, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-
- Animal-derived pulmonary surfactants include, without limitation, beractant, Alveofact (extracted from cow lung lavage fluid, manufactured by Boehringer Ingelheim), Survanta (extracted from minced cow lung with additional DPPC, palmitic acid and tripalmitin, manufactured by Abbvie), Beraksurf (extracted from minced cow lung with additional DPPC, palmitic acid and tripalmitin manufactured by Tekzima), calfactant (Infasurf, extracted from calf lung lavage), and proactant alfa (Curosurf®, extracted from material derived from minced pig lung).
- the surfactant is provided as a commercial product, for example, calfactant (Infasurf®).
- a “lung disease” refers to any congenital or acquired lung disease characterized by impairment of gas exchange. Lung diseases include, without limitation, surfactant deficiency, respiratory distress syndrome (RDS), adult respiratory distress syndrome (ARDS), meconium aspiration syndrome, pneumonia, cystic fibrosis, idiopathic pulmonary fibrosis, bronchitis, emphysema, and lung cancer.
- RDS respiratory distress syndrome
- ARDS adult respiratory distress syndrome
- meconium aspiration syndrome pneumonia
- cystic fibrosis idiopathic pulmonary fibrosis
- bronchitis emphysema
- emphysema emphysema
- a “lung condition” refers to any congenital or acquired lung condition, other than a lung disease, characterized by impairment of gas exchange. Lung conditions include, without limitation, atelectasis.
- preterm infant refers to an infant born at less than 32 weeks gestational age.
- an “infant” refers to a human baby less than one year old. In certain embodiments, an infant is a neonate or newborn.
- respiratory failure refers to compromise of lung gas exchange from any cause, characterized by diminished PaO 2 and/or increased PaCO 2 (without treatment) compared to normal values.
- respiratory failure is characterized by PaO 2 (without treatment) of less than or equal to 50 mm Hg.
- respiratory failure is sufficiently severe as to require supplemental oxygen.
- respiratory failure is sufficiently severe as to require mechanical ventilation.
- Respiratory failure can be acute or chronic.
- surfactant deficiency refers to any congenital or acquired deficiency of pulmonary surfactant. In certain embodiments, surfactant deficiency is accompanied by respiratory failure. Surfactant deficiency can be natural or it can be experimentally induced.
- RDS respiratory distress syndrome
- IRDS infant respiratory distress syndrome
- neonatal respiratory distress syndrome a respiratory distress syndrome
- surfactant deficiency disorder a respiratory distress syndrome disorder that affects newborns, especially preterm infants. It is believed to be caused by pulmonary surfactant deficiency due at least in part to immaturity of the type II alveolar cells which are the principal source of pulmonary surfactant. This syndrome is also variously known as infant respiratory distress syndrome (IRDS), neonatal respiratory distress syndrome, surfactant deficiency disorder, and hyaline membrane disease.
- IRDS infant respiratory distress syndrome
- neonatal respiratory distress syndrome atal respiratory distress syndrome
- surfactant deficiency disorder a hyaline membrane disease
- ARDS Acute respiratory distress syndrome
- ARDS is life-threatening condition that can develop principally in adults and is characterized by inflammation of and abnormal accumulation of fluid in alveoli of the lung.
- ARDS may be seen in the setting of a critical illness, e.g., severe pulmonary (pneumonia) or systemic infection (sepsis), following trauma, multiple blood transfusions, severe burns, severe pancreatitis, near-drowning, drug reactions, or inhalation injuries.
- a critical illness e.g., severe pulmonary (pneumonia) or systemic infection (sepsis)
- ARDS is characterized by: lung injury of acute onset, within 1 week of an apparent clinical insult and with progression of respiratory symptoms; bilateral opacities on chest imaging (chest X-ray or CT) not explained by other lung pathology; respiratory failure not explained by heart failure or volume overload; and decreased PaO 2 /FiO 2 ratio.
- liquid ventilation refers to a technique of mechanical ventilation in which the lungs are insufflated with an oxygenated perfluorochemical liquid rather than an oxygen-containing gas mixture.
- total liquid ventilation refers to a type of liquid ventilation in which the lungs are filled with PFC to a volume equivalent to the functional residual capacity, approximately 30 mL/kg, and a liquid ventilator is used to generate tidal breathing with perfluorocarbon.
- partial liquid ventilation refers to a type of liquid ventilation in which tracheal instillation of PFC liquid is used in combination with conventional gas mechanical ventilation.
- An aspect of the invention is a composition comprising silk fibroin and a perfluorocarbon.
- the silk fibroin is provided as an aqueous solution.
- the perfluorocarbon is provided as an aqueous solution.
- the composition is an aqueous solution comprising silk fibroin and a perfluorocarbon.
- the composition is an aqueous dispersion comprising silk fibroin and a perfluorocarbon.
- the composition is an aqueous emulsion comprising silk fibroin and a perfluorocarbon.
- the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- the perfluorocarbon is perfluorooctylbromide (1-Bromoperfluorooctane), e.g., perflubron.
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- the composition further comprises another active pharmaceutical agent (API).
- said other API is a drug, enzyme, antibody, or vaccine.
- said other API is a steroid, a diuretic, or deoxyribonuclease (DNAse) enzyme.
- Exemplary steroids include, without limitation, methylprednisone, beclomethasone, dexamethasone, budesonide, flunisolide, fluticasone, and hydrocortisone.
- Exemplary diuretics include, without limitation, furosemide, bumetanide, and amiloride.
- a further aspect of the invention is a composition comprising silk fibroin and a surfactant.
- the silk fibroin is provided as an aqueous solution.
- the surfactant is provided as an aqueous solution.
- the composition is an aqueous solution comprising silk fibroin and a surfactant.
- the composition is an aqueous dispersion comprising silk fibroin and a surfactant.
- the composition is an aqueous emulsion comprising silk fibroin and a surfactant.
- the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- the surfactant is a pulmonary surfactant.
- the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof.
- the surfactant is not a perfluorocarbon.
- the surfactant is calfactant.
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- the composition further comprises another active pharmaceutical agent (API).
- said other API is a drug, enzyme, antibody, or vaccine.
- said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- a yet further aspect of the invention is a composition comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the silk fibroin is provided as an aqueous solution.
- the perfluorocarbon is provided as an aqueous solution.
- the surfactant is provided as an aqueous solution.
- the composition is an aqueous solution comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the composition is an aqueous dispersion comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the composition is an aqueous emulsion comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- the perfluorocarbon is perfluorooctylbromide (1-Bromoperfluorooctane), e.g., perflubron.
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- the surfactant is a pulmonary surfactant.
- the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- the surfactant is calfactant.
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- the composition further comprises another active pharmaceutical agent (API).
- said other API is a drug, enzyme, antibody, or vaccine.
- said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- An aspect of the invention is a method of making a composition comprising silk fibroin and a perfluorocarbon.
- the method includes the step of placing the silk fibroin and the perfluorocarbon in an aqueous medium.
- the method further includes the step of mixing the silk fibroin and the perfluorocarbon in the aqueous medium.
- the mixing can be accomplished by any suitable means, including, without limitation, stirring, rocking, shaking, and vortexing.
- the silk fibroin is provided as an aqueous solution.
- the perfluorocarbon is provided as an aqueous solution.
- the composition is an aqueous solution comprising silk fibroin and a perfluorocarbon.
- the composition is an aqueous dispersion comprising silk fibroin and a perfluorocarbon.
- the composition is an aqueous emulsion comprising silk fibroin and a perfluorocarbon.
- the method comprises placing the silk fibroin and the perfluorocarbon in a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- the perfluorocarbon is perfluorooctylbromide, e.g., perflubron.
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- the method further comprises contacting the silk fibroin and the perfluorocarbon with another active pharmaceutical agent (API).
- said other API is a drug, enzyme, antibody, or vaccine.
- said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- An aspect of the invention is a method of making a composition comprising silk fibroin and a surfactant.
- the method includes the step of placing the silk fibroin and the surfactant in an aqueous medium.
- the method further includes the step of mixing the silk fibroin and the surfactant in the aqueous medium.
- the mixing can be accomplished by any suitable means, including, without limitation, stirring, rocking, shaking, and vortexing.
- the silk fibroin is provided as an aqueous solution.
- the surfactant is provided as an aqueous solution.
- the composition is an aqueous solution comprising silk fibroin and a surfactant.
- the composition is an aqueous dispersion comprising silk fibroin and a surfactant.
- the composition is an aqueous emulsion comprising silk fibroin and a surfactant.
- the method comprises placing the silk fibroin and the surfactant in a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- the surfactant is a pulmonary surfactant.
- the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- the surfactant is calfactant.
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- the method further comprises contacting the silk fibroin and the surfactant with another active pharmaceutical agent (API).
- said other API is a drug, enzyme, antibody, or vaccine.
- said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- a yet further aspect of the invention is a method of making a composition comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the method includes the step of placing the silk fibroin, the perfluorocarbon, and the surfactant in an aqueous medium.
- the method further includes the step of mixing the silk fibroin, the perfluorocarbon, and the surfactant in the aqueous medium.
- the mixing can be accomplished by any suitable means, including, without limitation, stirring, rocking, shaking, and vortexing.
- the silk fibroin is provided as an aqueous solution.
- the perfluorocarbon is provided as an aqueous solution.
- the surfactant is provided as an aqueous solution.
- the composition is an aqueous solution comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the composition is an aqueous dispersion comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the composition is an aqueous emulsion comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the method comprises placing the silk fibroin, perfluorocarbon, and surfactant in a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- the perfluorocarbon is perfluorooctylbromide (1-Bromoperfluorooctane), e.g., perflubron.
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- the surfactant is a pulmonary surfactant.
- the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- the surfactant is calfactant.
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- the method further comprises the step of contacting the silk fibroin, perfluorocarbon, and surfactant with an active pharmaceutical agent (API).
- said other API is a drug, enzyme, antibody, or vaccine.
- said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- An aspect of the invention is a method of treating a lung disease or lung condition, comprising administering a therapeutically effective amount of a composition comprising silk fibroin and a perfluorocarbon to an airway of a subject in need thereof.
- the terms “treat” and “treating” refer to reducing or ameliorating at least one sign or symptom of a disease or condition of a subject having said disease or condition. In certain embodiments, the terms “treat” and “treating” encompass curing a disease or condition of a subject having said disease or condition.
- a therapeutically effective amount refers to an amount sufficient to achieve a desired therapeutic result in a subject.
- a therapeutically effective amount can refers to an amount sufficient to reduce or ameliorate at least one sign or symptom of a disease or condition of a subject having said disease or condition.
- an “airway” refers to any conducting or gas-exchanging anatomical structure.
- an airway is any one or combination of trachea, bronchi, bronchioles, and alveoli.
- a “subject” refers to a living animal.
- a subject is a mammal.
- a subject is a mammal selected from the group consisting of mice, rats, hamsters, guinea pigs, rabbits, goats, sheep, cats, dogs, pigs, horses, cows, and non-human primates.
- a subject is a human.
- a subject is a preterm infant.
- a subject is an infant.
- a subject is a human 1 to 18 years of age. In some embodiments, a subject is an adult human.
- the silk fibroin is provided as an aqueous solution.
- the perfluorocarbon is provided as an aqueous solution.
- the composition is an aqueous solution comprising silk fibroin and a perfluorocarbon.
- the composition is an aqueous dispersion comprising silk fibroin and a perfluorocarbon.
- the composition is an aqueous emulsion comprising silk fibroin and a perfluorocarbon.
- the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- the perfluorocarbon is perfluorooctylbromide (1-Bromoperfluorooctane), e.g., perflubron.
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- the composition further comprises another active pharmaceutical agent (API).
- said other API is a drug, enzyme, antibody, or vaccine.
- said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- the subject is a preterm infant.
- the subject is an infant.
- the subject is an adult human.
- the lung disease or lung condition is selected from the group consisting of respiratory failure, surfactant deficiency, respiratory distress syndrome (RDS), adult respiratory distress syndrome (ARDS), meconium aspiration syndrome, hyaline membrane disease, pneumonia, cystic fibrosis, idiopathic pulmonary fibrosis, atelectasis, and any combination thereof.
- the lung disease or lung condition is respiratory distress syndrome (RDS).
- RDS respiratory distress syndrome
- the administering comprises liquid ventilation.
- the liquid ventilation is total liquid ventilation.
- the liquid ventilation is partial liquid ventilation.
- a further aspect of the invention is a method of treating a lung disease or lung condition, comprising administering a therapeutically effective amount of a composition comprising silk fibroin and a surfactant to an airway of a subject in need thereof.
- the silk fibroin is provided as an aqueous solution.
- the surfactant is provided as an aqueous solution.
- the composition is an aqueous solution comprising silk fibroin and a surfactant.
- the composition is an aqueous dispersion comprising silk fibroin and a surfactant.
- the composition is an aqueous emulsion comprising silk fibroin and a surfactant.
- the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- the surfactant is a pulmonary surfactant.
- the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- the surfactant is calfactant.
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- the composition further comprises another active pharmaceutical agent (API).
- said other API is a drug, enzyme, antibody, or vaccine.
- said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- the subject is a preterm infant.
- the subject is an infant. In certain embodiments, the subject is an adult human.
- the lung disease or lung condition is selected from the group consisting of respiratory failure, surfactant deficiency, respiratory distress syndrome (RDS), adult respiratory distress syndrome (ARDS), meconium aspiration syndrome, hyaline membrane disease, pneumonia, cystic fibrosis, idiopathic pulmonary fibrosis, atelectasis, and any combination thereof.
- the lung disease or lung condition is respiratory distress syndrome (RDS).
- RDS respiratory distress syndrome
- the administering comprises liquid ventilation.
- the liquid ventilation is total liquid ventilation.
- the liquid ventilation is partial liquid ventilation.
- a yet further aspect of the invention is a method of treating a lung disease or lung condition, comprising administering a therapeutically effective amount of a composition comprising silk fibroin, a perfluorocarbon, and a surfactant to an airway of a subject in need thereof.
- the silk fibroin is provided as an aqueous solution.
- the perfluorocarbon is provided as an aqueous solution.
- the surfactant is provided as an aqueous solution.
- the composition is an aqueous solution comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the composition is an aqueous dispersion comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the composition is an aqueous emulsion comprising silk fibroin, a perfluorocarbon, and a surfactant.
- the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- the perfluorocarbon is perfluorooctylbromide (1-Bromoperfluorooctane), e.g., perflubron.
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- the surfactant is a pulmonary surfactant.
- the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- the surfactant is calfactant.
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- the composition further comprises another active pharmaceutical agent (API).
- said other API is a drug, enzyme, antibody, or vaccine.
- said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- the subject is a human.
- the subject is a preterm infant.
- the subject is an infant.
- the subject is an adult human.
- the lung disease or lung condition is selected from the group consisting of respiratory failure, surfactant deficiency, respiratory distress syndrome (RDS), adult respiratory distress syndrome (ARDS), meconium aspiration syndrome, hyaline membrane disease, pneumonia, cystic fibrosis, idiopathic pulmonary fibrosis, atelectasis, and any combination thereof.
- the lung disease or lung condition is respiratory distress syndrome (RDS).
- RDS respiratory distress syndrome
- the administering comprises liquid ventilation.
- the liquid ventilation is total liquid ventilation.
- the liquid ventilation is partial liquid ventilation.
- compositions of the invention can be formulated for administration to lung.
- a composition of the invention can be formulated with a pharmaceutically acceptable carrier, wherein the composition is provided in a therapeutically effective amount within a volume suitable for administration to an airway of a subject to be treated.
- a “pharmaceutically acceptable carrier” refers to a biologically compatible aqueous fluid, e.g., water, normal saline, Ringer's solution, solution buffered to physiologic pH (pH 6.8-7.4).
- the pharmaceutically acceptable carrier can optionally include any one or more of salts, buffering agents, osmotically active agents, preservatives, and coloring agents, such as are well known in the pharmaceutical arts. See, e.g., Remington's The Science and Practice of Pharmacy , Lloyd V. Allen, Jr, editor, Philadelphia, Pa.: Pharmaceutical Press. 2012.
- composition of the invention so formulated can be instilled into an airway of the lung, e.g., via an endotracheal tube. Dosing may involve any one or combination of (i) lavage, (ii) partial liquid ventilation, and (iii) total liquid ventilation.
- Administration can be accomplished in a single dose or in multiple (i.e., two or more) doses.
- each dose can be the same, or at least one dose can differ from another dose.
- dosing can be based on corresponding surfactant alone.
- dosing can be based on corresponding PFC alone.
- the composition is administered once daily, twice daily, three times daily, four times daily, or more. In certain embodiments, the composition is administered every other day, every third day, every fourth day, every fifth day, every sixth day, or every seventh day.
- the administering physician or medical professional will be able to assess and adjust the dose and frequency of dosing based on such parameters as body weight, lung volumes, age, general medical condition, other medical conditions, and laboratory values such as O 2 saturation, arterial blood gases (ABGs), and radiographic examination of the lungs.
- An aspect of the invention is a kit comprising silk fibroin in a first container and a perfluorocarbon in a second container.
- the kit may be conveniently presented with the components packaged together, for example in a box, tray, or foil pouch.
- the component silk fibroin and perfluorocarbon can be combined by an end user to make a composition in accordance with the invention.
- An aspect of the invention is a kit comprising silk fibroin in a first container and a surfactant in a second container.
- the kit may be conveniently presented with the components packaged together, for example in a box, tray, or foil pouch.
- the component silk fibroin and surfactant can be combined by an end user to make a composition in accordance with the invention.
- An aspect of the invention is a kit comprising silk fibroin in a first container, a perfluorocarbon in a second container, and a surfactant in a third container.
- the kit may be conveniently presented with the components packaged together, for example in a box, tray, or foil pouch.
- the component silk fibroin, perfluorocarbon, and surfactant can be combined by an end user to make a composition in accordance with the invention.
- kits can further include written instructions directing an end user how to assemble and/or administer the various components.
- kits can further include an applicator or other delivery device suitably constructed and arranged for use in administering the various and/or assembled components to a subject in need thereof.
- applicator or delivery device can be a syringe.
- Silk fibroin was obtained from Silk lab, Tufts Science and Technology Center, 4 Colby St Biomed Eng Dept., Medford, Mass.
- PFC was obtained from Origen Biomedical, Austin, Tex.
- Infasurf Lung Surfactant called Infasurf was obtained from ONY, Inc. 1576 Sweet Home Road, Amherst, N.Y. 14228.
- Aqueous preparations of silk fibroin and perfluorocarbon (PFC); silk fibroin and surfactant; PFC and surfactant; and silk fibroin, PFC, and surfactant were prepared and visually inspected for homogeneity. Selected properties of silk fibroin and PFC are shown in Table 1. Selected properties of silk fibroin and surfactant are shown in Table 2. Representative results are shown in FIGS. 1A-1E .
- Silk Fibroin Surfactant Constituents protein and water protein and lipid Proteins Hydrophobic (HMW) Hydrophobic (BC+) Hydrophilic (LMW) Hydrophilic (A ⁇ ) Surface Tension ?? Low (14-18 Dynes/cm) H 2 O: 70 Dynes/cm) Lung: 25 Dynes/cm pH 6-6.5 5.0-6.2
- Silk fibroin and surfactant formed a homogeneous mixture. Surfactant and PFC mixture was nonhomogeneous. Silk fibroin, PFC, and surfactant was homogeneous after vigorous shaking.
- a New Zealand white rabbit was used to test proof of concept.
- the animal weighing 1.58 kg anesthetized and after instrumentation, anesthesia was administered continuously as per protocol.
- the rabbit was intubated orally and ventilated on assist/control mode at 30 breaths/min, 0.4 fraction of inspired oxygen (FiO 2 ), 0.35 sec inspiratory time, 4 cm H 2 O positive end expiratory pressure (PEEP), and tidal volume targeted to 7 mL/kg.
- the lungs were lavaged 4 times with 30 mL/kg of normal (0.9%) saline several times until blood gases were consistent with surfactant deficiency status.
- Rats, rabbits, or sheep are anesthetized, intubated, ventilated, and made surfactant-deficient in a manner similar to Example 2.
- Animals are then treated with test agent selected from (i) silk fibroin alone; (ii) PFC alone; (iii) surfactant alone; (iv) vehicle alone; (v) silk fibroin and PFC; (vi) silk fibroin and surfactant; (vii) PFC and surfactant; and/or (viii) silk fibroin, PFC, and surfactant by instillation into the lungs.
- Arterial blood gas (ABG), mean arterial pressure (MAP), and arterial blood pressures are measured prior to administration of test agent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This application claims benefit of priority to U.S. Provisional Patent Application No. 62/574,993, filed Oct. 20, 2017, the entire content of which is incorporated herein by reference.
- The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 11, 2018, is named 606117_GUS-021PC_ST25.txt and is 392 bytes in size.
- Liquid silk is produced by a variety of insects and spiders. The best characterized silks are cocoon silk from the domesticated silkworm Bombyx mori. Bombyx mori silk is composed of a core protein, silk fibroin, and a glue-like coating consisting of a nonfilamentous protein, sericin. The core protein of Bombyx mori silk is made from two structural proteins, fibroin heavy chain (˜325 kDa) and light chain (˜25 kDa). The fibroin heavy chain protein consists of layers of antiparallel beta sheets, and its primary structure mainly consists of the recurrent hydrophobic amino acid sequence Gly-Ser-Gly-Ala-Gly-Ala (GSGAGA) (SEQ ID NO:1). Silk fibroin is a natural or synthetic polymer used in textile production, medical sutures, and more recently as a scaffold for tissue regeneration and other medical applications.
- Because of their characteristics, perfluorochemicals have been proposed for use as perfusates for organs, as blood substitutes, and as liquids for liquid lavaging or liquid ventilation of the lungs. Perfluorocarbons (PFCs) are chemically inert materials that are known to enable oxygen transport in mammalian systems. For example, rats have been shown to survive total immersion in a liquid perfluorochemical saturated with oxygen. The high solubility of oxygen in most perfluorochemicals enables the rat to “breathe” the perfluorochemical. This process, and its variants, are commonly referred to as liquid ventilation. In one form of liquid ventilation, known as perfluorochemical assisted gas exchange (PAGE), a pure fluorochemical liquid is instilled into the lungs of an animal in an amount equal to the functional residual capacity of the lungs. The animal then is connected to a mechanical ventilator which delivers tidal volumes of a breathable gas to the lungs. However, the PAGE technique is extremely limited with respect to the ability to deliver drugs to the lungs. Because perfluorochemicals are both hydrophobic and lipophobic, very few medicaments other than halocarbon anesthetics may be delivered to the lungs using such liquid breathing techniques.
- Surfactant therapy has substantially improved the survival of premature infants with respiratory distress syndrome (RDS), which results from a deficiency of pulmonary surfactant. However, exogenous surfactant is not uniformly effective in treating preterm infants with RDS because the surfactant fails to reach atelectatic alveoli. Perfluorocarbons have been shown to be effective in recruiting atelectatic areas but do not replace impaired endogenous surfactant.
- It has now been discovered by the present inventor that silk fibroin, PFC, and lung surfactant can be combined to form an aqueous emulsion, and that such preparation can (i) prolong the effect of lung surfactant, (ii) lead to a substantially more rapid improvement of oxygenation compared to lung surfactant alone, and (iii) lead to a more homogenous distribution of surfactant. Importantly, such preparation also provides substantial improvement in lung volumes, lung compliance, oxygenation, and ventilation compared to surfactant or PFC alone. This mixture will improve delivery to lung of both surfactant and PFC, and it will find use in the treatment of various lung diseases and conditions, notably including RDS in preterm infants. This mixture may also be used as lung lavage in other infant disease conditions such as MAS (meconium aspiration syndrome) and/or pneumonia and to improve lung function.
- An aspect of the invention is a composition comprising silk fibroin and a perfluorocarbon. In certain embodiments, the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- An aspect of the invention is a composition comprising silk fibroin and a surfactant. In certain embodiments, the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- An aspect of the invention is a composition comprising silk fibroin, a perfluorocarbon, and a surfactant. In certain embodiments, the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof. In certain embodiments, the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- In certain embodiments, any one of the foregoing compositions further comprises a drug, enzyme, antibody, or vaccine.
- An aspect of the invention is a method of making any one of the foregoing compositions.
- An aspect of the invention is a method of treating a lung disease or lung condition, comprising administering a therapeutically effective amount of any one of the aforementioned compositions to an airway of a subject in need thereof. In certain embodiments, the subject is a human. In certain embodiments, the subject is a preterm infant. In certain embodiments, the subject is an infant. In certain embodiments, the lung disease or lung condition is selected from the group consisting of respiratory failure, surfactant deficiency, respiratory distress syndrome (RDS), adult respiratory distress syndrome (ARDS), meconium aspiration syndrome, hyaline membrane disease, pneumonia, cystic fibrosis, idiopathic pulmonary fibrosis, atelectasis, and any combination thereof. In certain embodiments, the lung disease or lung condition is respiratory distress syndrome (RDS). In certain embodiments, the administering comprises liquid ventilation. In certain embodiments, the administering comprises lung lavage, e.g., bronchoalveolar lavage (BAL).
- An aspect of the invention is a kit comprising components of any one of the aforementioned compositions.
-
FIG. 1A is a photographic image depicting an aqueous mixture of silk fibroin and PFC (perfluorooctylbromide). -
FIG. 1B is a photographic image depicting an aqueous mixture of silk fibroin and surfactant. -
FIG. 1C is a photographic image depicting an aqueous mixture of PFC and surfactant. -
FIG. 1D is a photographic image depicting an aqueous mixture of silk fibroin, surfactant, and PFC prior to vigorous shaking. -
FIG. 1E is a photographic image depicting an aqueous mixture of silk fibroin, surfactant, and PFC after vigorous shaking. - Compositions of the invention include aqueous mixtures of silk fibroin and (a) perfluorocarbon, (b) surfactant, or (c) both perfluorocarbon and surfactant. Each of the components silk fibroin, perfluorocarbon, and surfactant, is deemed to be an active agent. As disclosed herein, in certain embodiments the compositions or mixtures of the invention can further comprise one or more additional agents, including other active pharmaceutical ingredients (APIs). Also as disclosed herein, the compositions of the invention are believed to be useful in the treatment of certain lung diseases and lung conditions, including ARDS.
- The silk fibroin component is believed to facilitate the delivery, and therefore enhance the efficacy, of each component with which it is combined in accordance with the compositions of the invention. In fact, it is believed that the combination of silk fibroin, perfluorocarbon, and surfactant exhibits synergistic biological properties over any pair of these three components.
- In certain embodiments, the aqueous mixtures are dispersions. In certain embodiments, the aqueous mixtures are emulsions. In certain embodiments, the aqueous mixtures are microemulsions. As will be discussed below, the various components can be combined in various relative amounts or ratios.
- As used herein, a “silk fibroin” or “fibroin” refers to natural or recombinant silk fibroin. In certain embodiments, the silk fibroin is derived from the domesticated Bombyx mori silkworm. In certain embodiments, “silk fibroin” refers to an aqueous solution containing natural or recombinant silk fibroin protein. See, for example, U.S. Pat. No. 7,635,755, International Patent Application Publication No. WO 97/08315, and U.S. Pat. No. 5,245,012, the entire contents of which are incorporated herein by reference.
- Silk is a well described natural fiber produced by the silkworm, Bombyx mori, which has been used traditionally in the form of threads in textiles for thousands of years. This silk contains a fibrous protein termed fibroin (both heavy and light chains) that form the thread core, and glue-like proteins termed sericin that surround the fibroin fibers to cement them together. The fibroin is a highly insoluble protein containing up to 90% the amino acids glycine, alanine and serine leading to β-pleated sheet formation in the fibers (Asakura, et al., Encyclopedia of Agricultural Science, Arntzen, C. J., Ritter, E. M. Eds.; Academic Press: New York, N.Y., 1994; Vol. 4, pp 1-11).
- Silk fibroin has been proposed as a vehicle for drug delivery. See, for example, Wenk et al. Biomaterials 31: 1403-13 (2010), and Wenk et al. J Control Release 150: 128-41 (2011), the entire contents of which are incorporated herein by reference. Silk fibroin has unique self-assembly process (driving force: hydrophobicity and electrostatic interactions), and it acts like a cocoon for biological matter. Cells show normal growth and proliferation in the presence of silk fibroin. A common and straightforward way to incorporate drugs into the fabrication of silk fibroin delivery system is by dissolving or mixing them directly into silk fibroin solution. Addition of enzymes or antibodies or vaccines to liquid silk solution (the self-assembly process) preserves the biological function of these compounds.
- In certain embodiments, the silk fibroin is provided as a commercial product, for example, silk fibroin 50 mg/mL in aqueous solution (Sigma-Aldrich).
- As used herein, a “perfluorocarbon” or “PFC” refers to a hydrocarbon, or optionally a substituted hydrocarbon, in which all C—H bonds have been replaced by C—F bonds. Perfluorocarbons include perfluoroalkanes, perfluoroalkenes, perfluoroalkynes, and perfluoroaromatic compounds. In certain embodiments, a “perfluorocarbon” refers to a perfluoroalkane. The alkane portion can be unbranched, branched, or cyclical. There are five perfluoroalkane gases: tetrafluoromethane (bp −128° C.), hexafluoroethane (bp −78.2° C.), octafluoropropane (bp −36.5° C.), perfluoro-n-butane (bp −2.2° C.), and perfluoro-iso-butane (bp −1° C.). Nearly all other fluoroalkanes are liquids.
- PFC liquids have low surface tension and at atmospheric pressure, large amounts of oxygen and carbon dioxide dissolve in them. For example, PFC carries 20 times more oxygen than saline/water and twice that of blood. The 02 diffusion rate from PFC-filled alveoli to the alveolar capillaries is quite high. Clear, colorless, odorless, non-conducting, and non-flammable, PFCs are insoluble in water and only sparingly soluble in lipid. PFCs are not metabolized in body tissues.
- In certain embodiments, a perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof. In certain embodiments, a perfluorocarbon is perfluorooctylbromide.
- A perfluorocarbon may be presented in a gas or liquid form. Liquid forms may include a water-in-perfluorocarbon stable liquid dispersion or a perfluorocarbon-in-water microemulsion. Homogenous water-in-perfluorochemical stable liquid dispersions are disclosed in U.S. Pat. No. 5,770,585, the entire content of which is incorporated herein by reference.
- In certain embodiments, a perfluorocarbon is provided as a commercial product, for example, LiquiVent® (perfluorooctylbromide; perflubron; Origen Biomedical, Austin, Tex.).
- As used herein, a “surfactant” refers to a compound that lowers the surface tension between two liquids or between a liquid and a solid. In certain embodiments, a surfactant is a pulmonary surfactant.
- Pulmonary surfactant is a surface-active phospholipoprotein complex formed by type II alveolar cells of the lung. The proteins and lipids that make up the surfactant have both hydrophilic and hydrophobic regions. By adsorbing to the air-water interface of alveoli, with hydrophilic head groups in the water and the hydrophobic tails facing towards the air, the main lipid component of surfactant, dipalmitoylphosphatidylcholine (DPPC), reduces surface tension. Pulmonary surfactant increases pulmonary compliance and facilitates recruitment of collapsed (atelectatic) airways. Most preterm infants are surfactant-deficient at birth and as a result have respiratory problems, including respiratory distress syndrome (RDS). RDS is a major cause of premature infant morbidity and mortality.
- Pulmonary surfactants generally include synthetic pulmonary surfactants and animal-derived pulmonary surfactants. Both synthetic pulmonary surfactants and animal-derived pulmonary surfactants are useful in the invention.
- Synthetic pulmonary surfactants include, without limitation, colfosceril palmitate (Exosurf), a mixture of dipalmitoylphosphatidylcholine (DPPC) with hexadecanol and tyloxapol; pumactant, a mixture of DPPC and phosphatidylglycerol (PG); KL-4, a mixture of DPPC, palmitoyl-oleoyl phosphatidylglycerol, and palmitic acid, combined with a 21 amino acid synthetic peptide that mimics the structural characteristics of surfactant protein B (SP-B); venticute, a mixture of DPPC, PG, palmitic acid, and recombinant surfactant protein C (SP-C); and lucinactant (Surfaxin), a mixture of KL4 acetate, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (as the sodium salt), and palmitic acid. PG consists of an L-glycerol 3-phosphate backbone ester-bonded to either saturated or unsaturated fatty acids on carbons 1 and 2.
- Animal-derived pulmonary surfactants include, without limitation, beractant, Alveofact (extracted from cow lung lavage fluid, manufactured by Boehringer Ingelheim), Survanta (extracted from minced cow lung with additional DPPC, palmitic acid and tripalmitin, manufactured by Abbvie), Beraksurf (extracted from minced cow lung with additional DPPC, palmitic acid and tripalmitin manufactured by Tekzima), calfactant (Infasurf, extracted from calf lung lavage), and proactant alfa (Curosurf®, extracted from material derived from minced pig lung).
- In certain embodiments, the surfactant is provided as a commercial product, for example, calfactant (Infasurf®).
- As used herein, a “lung disease” refers to any congenital or acquired lung disease characterized by impairment of gas exchange. Lung diseases include, without limitation, surfactant deficiency, respiratory distress syndrome (RDS), adult respiratory distress syndrome (ARDS), meconium aspiration syndrome, pneumonia, cystic fibrosis, idiopathic pulmonary fibrosis, bronchitis, emphysema, and lung cancer.
- As used herein, a “lung condition” refers to any congenital or acquired lung condition, other than a lung disease, characterized by impairment of gas exchange. Lung conditions include, without limitation, atelectasis.
- As used herein, a “preterm infant” refers to an infant born at less than 32 weeks gestational age.
- As used herein, an “infant” refers to a human baby less than one year old. In certain embodiments, an infant is a neonate or newborn.
- As used herein, “respiratory failure” refers to compromise of lung gas exchange from any cause, characterized by diminished PaO2 and/or increased PaCO2 (without treatment) compared to normal values. In certain embodiments, respiratory failure is characterized by PaO2 (without treatment) of less than or equal to 50 mm Hg. In certain embodiments, respiratory failure is sufficiently severe as to require supplemental oxygen. In certain embodiments, respiratory failure is sufficiently severe as to require mechanical ventilation. Respiratory failure can be acute or chronic.
- As used herein, “surfactant deficiency” refers to any congenital or acquired deficiency of pulmonary surfactant. In certain embodiments, surfactant deficiency is accompanied by respiratory failure. Surfactant deficiency can be natural or it can be experimentally induced.
- As used herein, the terms “respiratory distress syndrome” or “RDS” refer to a breathing disorder that affects newborns, especially preterm infants. It is believed to be caused by pulmonary surfactant deficiency due at least in part to immaturity of the type II alveolar cells which are the principal source of pulmonary surfactant. This syndrome is also variously known as infant respiratory distress syndrome (IRDS), neonatal respiratory distress syndrome, surfactant deficiency disorder, and hyaline membrane disease.
- Acute respiratory distress syndrome (ARDS) is life-threatening condition that can develop principally in adults and is characterized by inflammation of and abnormal accumulation of fluid in alveoli of the lung. ARDS may be seen in the setting of a critical illness, e.g., severe pulmonary (pneumonia) or systemic infection (sepsis), following trauma, multiple blood transfusions, severe burns, severe pancreatitis, near-drowning, drug reactions, or inhalation injuries. ARDS is characterized by: lung injury of acute onset, within 1 week of an apparent clinical insult and with progression of respiratory symptoms; bilateral opacities on chest imaging (chest X-ray or CT) not explained by other lung pathology; respiratory failure not explained by heart failure or volume overload; and decreased PaO2/FiO2 ratio.
- As used herein, “liquid ventilation” refers to a technique of mechanical ventilation in which the lungs are insufflated with an oxygenated perfluorochemical liquid rather than an oxygen-containing gas mixture. For a review, see Tawfic et al., Oman Med J 26:(1):4-9 (2011).
- As used herein, “total liquid ventilation” refers to a type of liquid ventilation in which the lungs are filled with PFC to a volume equivalent to the functional residual capacity, approximately 30 mL/kg, and a liquid ventilator is used to generate tidal breathing with perfluorocarbon.
- As used herein, “partial liquid ventilation” refers to a type of liquid ventilation in which tracheal instillation of PFC liquid is used in combination with conventional gas mechanical ventilation.
- An aspect of the invention is a composition comprising silk fibroin and a perfluorocarbon. In certain embodiments, the silk fibroin is provided as an aqueous solution. In certain embodiments, the perfluorocarbon is provided as an aqueous solution. In certain embodiments, the composition is an aqueous solution comprising silk fibroin and a perfluorocarbon. In certain embodiments, the composition is an aqueous dispersion comprising silk fibroin and a perfluorocarbon. In certain embodiments, the composition is an aqueous emulsion comprising silk fibroin and a perfluorocarbon.
- In certain embodiments, the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- In certain embodiments, the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- In certain embodiments, the perfluorocarbon is perfluorooctylbromide (1-Bromoperfluorooctane), e.g., perflubron.
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v). For example, in certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- In certain embodiments, the composition further comprises another active pharmaceutical agent (API). In certain embodiments, said other API is a drug, enzyme, antibody, or vaccine. In certain embodiments, said other API is a steroid, a diuretic, or deoxyribonuclease (DNAse) enzyme.
- Exemplary steroids include, without limitation, methylprednisone, beclomethasone, dexamethasone, budesonide, flunisolide, fluticasone, and hydrocortisone.
- Exemplary diuretics include, without limitation, furosemide, bumetanide, and amiloride.
- A further aspect of the invention is a composition comprising silk fibroin and a surfactant. In certain embodiments, the silk fibroin is provided as an aqueous solution. In certain embodiments, the surfactant is provided as an aqueous solution. In certain embodiments, the composition is an aqueous solution comprising silk fibroin and a surfactant. In certain embodiments, the composition is an aqueous dispersion comprising silk fibroin and a surfactant. In certain embodiments, the composition is an aqueous emulsion comprising silk fibroin and a surfactant.
- In certain embodiments, the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- In certain embodiments, the surfactant is a pulmonary surfactant.
- In certain embodiments, the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon. In certain embodiments, the surfactant is calfactant.
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v). For example, in certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- In certain embodiments, the composition further comprises another active pharmaceutical agent (API). In certain embodiments, said other API is a drug, enzyme, antibody, or vaccine. In certain embodiments, said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- A yet further aspect of the invention is a composition comprising silk fibroin, a perfluorocarbon, and a surfactant. In certain embodiments, the silk fibroin is provided as an aqueous solution. In certain embodiments, the perfluorocarbon is provided as an aqueous solution. In certain embodiments, the surfactant is provided as an aqueous solution. In certain embodiments, the composition is an aqueous solution comprising silk fibroin, a perfluorocarbon, and a surfactant. In certain embodiments, the composition is an aqueous dispersion comprising silk fibroin, a perfluorocarbon, and a surfactant. In certain embodiments, the composition is an aqueous emulsion comprising silk fibroin, a perfluorocarbon, and a surfactant.
- In certain embodiments, the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- In certain embodiments, the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- In certain embodiments, the perfluorocarbon is perfluorooctylbromide (1-Bromoperfluorooctane), e.g., perflubron.
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v). For example, in certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- In certain embodiments, the surfactant is a pulmonary surfactant.
- In certain embodiments, the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- In certain embodiments, the surfactant is calfactant.
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v). For example, in certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- In certain embodiments, the composition further comprises another active pharmaceutical agent (API). In certain embodiments, said other API is a drug, enzyme, antibody, or vaccine. In certain embodiments, said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- An aspect of the invention is a method of making a composition comprising silk fibroin and a perfluorocarbon. The method includes the step of placing the silk fibroin and the perfluorocarbon in an aqueous medium. In certain embodiments, the method further includes the step of mixing the silk fibroin and the perfluorocarbon in the aqueous medium. The mixing can be accomplished by any suitable means, including, without limitation, stirring, rocking, shaking, and vortexing.
- In certain embodiments, the silk fibroin is provided as an aqueous solution. In certain embodiments, the perfluorocarbon is provided as an aqueous solution. In certain embodiments, the composition is an aqueous solution comprising silk fibroin and a perfluorocarbon. In certain embodiments, the composition is an aqueous dispersion comprising silk fibroin and a perfluorocarbon. In certain embodiments, the composition is an aqueous emulsion comprising silk fibroin and a perfluorocarbon.
- In certain embodiments, the method comprises placing the silk fibroin and the perfluorocarbon in a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- In certain embodiments, the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- In certain embodiments, the perfluorocarbon is perfluorooctylbromide, e.g., perflubron.
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v). For example, in certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- In certain embodiments, the method further comprises contacting the silk fibroin and the perfluorocarbon with another active pharmaceutical agent (API). In certain embodiments, said other API is a drug, enzyme, antibody, or vaccine. In certain embodiments, said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- An aspect of the invention is a method of making a composition comprising silk fibroin and a surfactant. The method includes the step of placing the silk fibroin and the surfactant in an aqueous medium. In certain embodiments, the method further includes the step of mixing the silk fibroin and the surfactant in the aqueous medium. The mixing can be accomplished by any suitable means, including, without limitation, stirring, rocking, shaking, and vortexing.
- In certain embodiments, the silk fibroin is provided as an aqueous solution. In certain embodiments, the surfactant is provided as an aqueous solution. In certain embodiments, the composition is an aqueous solution comprising silk fibroin and a surfactant. In certain embodiments, the composition is an aqueous dispersion comprising silk fibroin and a surfactant. In certain embodiments, the composition is an aqueous emulsion comprising silk fibroin and a surfactant.
- In certain embodiments, the method comprises placing the silk fibroin and the surfactant in a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- In certain embodiments, the surfactant is a pulmonary surfactant.
- In certain embodiments, the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- In certain embodiments, the surfactant is calfactant.
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v). For example, in certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- In certain embodiments, the method further comprises contacting the silk fibroin and the surfactant with another active pharmaceutical agent (API). In certain embodiments, said other API is a drug, enzyme, antibody, or vaccine. In certain embodiments, said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- A yet further aspect of the invention is a method of making a composition comprising silk fibroin, a perfluorocarbon, and a surfactant. The method includes the step of placing the silk fibroin, the perfluorocarbon, and the surfactant in an aqueous medium. In certain embodiments, the method further includes the step of mixing the silk fibroin, the perfluorocarbon, and the surfactant in the aqueous medium. The mixing can be accomplished by any suitable means, including, without limitation, stirring, rocking, shaking, and vortexing.
- In certain embodiments, the silk fibroin is provided as an aqueous solution. In certain embodiments, the perfluorocarbon is provided as an aqueous solution. In certain embodiments, the surfactant is provided as an aqueous solution. In certain embodiments, the composition is an aqueous solution comprising silk fibroin, a perfluorocarbon, and a surfactant. In certain embodiments, the composition is an aqueous dispersion comprising silk fibroin, a perfluorocarbon, and a surfactant. In certain embodiments, the composition is an aqueous emulsion comprising silk fibroin, a perfluorocarbon, and a surfactant.
- In certain embodiments, the method comprises placing the silk fibroin, perfluorocarbon, and surfactant in a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- In certain embodiments, the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- In certain embodiments, the perfluorocarbon is perfluorooctylbromide (1-Bromoperfluorooctane), e.g., perflubron.
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v). For example, in certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- In certain embodiments, the surfactant is a pulmonary surfactant.
- In certain embodiments, the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- In certain embodiments, the surfactant is calfactant.
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v). For example, in certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- In certain embodiments, the method further comprises the step of contacting the silk fibroin, perfluorocarbon, and surfactant with an active pharmaceutical agent (API). In certain embodiments, said other API is a drug, enzyme, antibody, or vaccine. In certain embodiments, said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- An aspect of the invention is a method of treating a lung disease or lung condition, comprising administering a therapeutically effective amount of a composition comprising silk fibroin and a perfluorocarbon to an airway of a subject in need thereof.
- As used herein, the terms “treat” and “treating” refer to reducing or ameliorating at least one sign or symptom of a disease or condition of a subject having said disease or condition. In certain embodiments, the terms “treat” and “treating” encompass curing a disease or condition of a subject having said disease or condition.
- As used herein, the term “therapeutically effective amount” refers to an amount sufficient to achieve a desired therapeutic result in a subject. For example, a therapeutically effective amount can refers to an amount sufficient to reduce or ameliorate at least one sign or symptom of a disease or condition of a subject having said disease or condition.
- As used herein, an “airway” refers to any conducting or gas-exchanging anatomical structure. In certain embodiments, an airway is any one or combination of trachea, bronchi, bronchioles, and alveoli.
- As used herein, a “subject” refers to a living animal. In certain embodiments, a subject is a mammal. In certain embodiments, a subject is a mammal selected from the group consisting of mice, rats, hamsters, guinea pigs, rabbits, goats, sheep, cats, dogs, pigs, horses, cows, and non-human primates. In certain embodiments, a subject is a human. In some embodiments, a subject is a preterm infant. In some embodiments, a subject is an infant. In some embodiments, a subject is a human 1 to 18 years of age. In some embodiments, a subject is an adult human.
- In certain embodiments, the silk fibroin is provided as an aqueous solution. In certain embodiments, the perfluorocarbon is provided as an aqueous solution. In certain embodiments, the composition is an aqueous solution comprising silk fibroin and a perfluorocarbon. In certain embodiments, the composition is an aqueous dispersion comprising silk fibroin and a perfluorocarbon. In certain embodiments, the composition is an aqueous emulsion comprising silk fibroin and a perfluorocarbon.
- In certain embodiments, the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- In certain embodiments, the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- In certain embodiments, the perfluorocarbon is perfluorooctylbromide (1-Bromoperfluorooctane), e.g., perflubron.
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v). For example, in certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- In certain embodiments, the composition further comprises another active pharmaceutical agent (API). In certain embodiments, said other API is a drug, enzyme, antibody, or vaccine. In certain embodiments, said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- In certain embodiments, the subject is a preterm infant.
- In certain embodiments, the subject is an infant.
- In certain embodiments, the subject is an adult human.
- In certain embodiments, the lung disease or lung condition is selected from the group consisting of respiratory failure, surfactant deficiency, respiratory distress syndrome (RDS), adult respiratory distress syndrome (ARDS), meconium aspiration syndrome, hyaline membrane disease, pneumonia, cystic fibrosis, idiopathic pulmonary fibrosis, atelectasis, and any combination thereof.
- In certain embodiments, the lung disease or lung condition is respiratory distress syndrome (RDS).
- In certain embodiments, the administering comprises liquid ventilation.
- In certain embodiments, the liquid ventilation is total liquid ventilation.
- In certain embodiments, the liquid ventilation is partial liquid ventilation.
- A further aspect of the invention is a method of treating a lung disease or lung condition, comprising administering a therapeutically effective amount of a composition comprising silk fibroin and a surfactant to an airway of a subject in need thereof.
- In certain embodiments, the silk fibroin is provided as an aqueous solution. In certain embodiments, the surfactant is provided as an aqueous solution. In certain embodiments, the composition is an aqueous solution comprising silk fibroin and a surfactant. In certain embodiments, the composition is an aqueous dispersion comprising silk fibroin and a surfactant. In certain embodiments, the composition is an aqueous emulsion comprising silk fibroin and a surfactant.
- In certain embodiments, the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- In certain embodiments, the surfactant is a pulmonary surfactant.
- In certain embodiments, the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- In certain embodiments, the surfactant is calfactant.
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v). For example, in certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- In certain embodiments, the composition further comprises another active pharmaceutical agent (API). In certain embodiments, said other API is a drug, enzyme, antibody, or vaccine. In certain embodiments, said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- In certain embodiments, the subject is a preterm infant.
- In certain embodiments, the subject is an infant. In certain embodiments, the subject is an adult human.
- In certain embodiments, the lung disease or lung condition is selected from the group consisting of respiratory failure, surfactant deficiency, respiratory distress syndrome (RDS), adult respiratory distress syndrome (ARDS), meconium aspiration syndrome, hyaline membrane disease, pneumonia, cystic fibrosis, idiopathic pulmonary fibrosis, atelectasis, and any combination thereof.
- In certain embodiments, the lung disease or lung condition is respiratory distress syndrome (RDS).
- In certain embodiments, the administering comprises liquid ventilation.
- In certain embodiments, the liquid ventilation is total liquid ventilation.
- In certain embodiments, the liquid ventilation is partial liquid ventilation.
- A yet further aspect of the invention is a method of treating a lung disease or lung condition, comprising administering a therapeutically effective amount of a composition comprising silk fibroin, a perfluorocarbon, and a surfactant to an airway of a subject in need thereof.
- In certain embodiments, the silk fibroin is provided as an aqueous solution. In certain embodiments, the perfluorocarbon is provided as an aqueous solution. In certain embodiments, the surfactant is provided as an aqueous solution. In certain embodiments, the composition is an aqueous solution comprising silk fibroin, a perfluorocarbon, and a surfactant. In certain embodiments, the composition is an aqueous dispersion comprising silk fibroin, a perfluorocarbon, and a surfactant. In certain embodiments, the composition is an aqueous emulsion comprising silk fibroin, a perfluorocarbon, and a surfactant.
- In certain embodiments, the composition further comprises a pharmaceutically acceptable carrier, such as is described elsewhere herein.
- In certain embodiments, the perfluorocarbon is selected from the group consisting of perfluoro-n-butyltetrahydrofuran, perfluorodichlorooctane, perfluorobischlorobutylether, perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyl-octahydroquinolidizine, perfluoro-N-methyl-decahydroquinoline, F-methyl-1-oxa-decalin, perfluoro-bicyclo(5.3.0)-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene, chlorinated perfluorocarbons, and any combination thereof.
- In certain embodiments, the perfluorocarbon is perfluorooctylbromide (1-Bromoperfluorooctane), e.g., perflubron.
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:1 (v/v). For example, in certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 (v/v). In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:1 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to perfluorocarbon is about 1:2 to 1:1 (v/v).
- In certain embodiments, the surfactant is a pulmonary surfactant.
- In certain embodiments, the surfactant is selected from the group consisting of egg yolk phospholipid, polyalkyleneoxides, 1,2-dialkylglycero-3-phosphoryl cholines, 1,3-dialkylglycero-2-phosphoryl cholines, perfluorinated polyoxyethylenes, and any combination thereof. In certain embodiments, the surfactant is not a perfluorocarbon.
- In certain embodiments, the surfactant is calfactant.
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2 (v/v). For example, in certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2.5 (v/v). In certain embodiments, the ratio of silk fibroin to surfactant is about 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:6 to 1:5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:5 to 1:4 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:2.5 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:4 to 1:3 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2 (v/v).
- In certain embodiments, the ratio of silk fibroin to surfactant is about 1:3 to 1:2.5 (v/v).
- In certain embodiments, the composition further comprises another active pharmaceutical agent (API). In certain embodiments, said other API is a drug, enzyme, antibody, or vaccine. In certain embodiments, said other API is a steroid, diuretic, or deoxyribonuclease (DNAse) enzyme.
- In certain embodiments, the subject is a human.
- In certain embodiments, the subject is a preterm infant.
- In certain embodiments, the subject is an infant.
- In certain embodiments, the subject is an adult human.
- In certain embodiments, the lung disease or lung condition is selected from the group consisting of respiratory failure, surfactant deficiency, respiratory distress syndrome (RDS), adult respiratory distress syndrome (ARDS), meconium aspiration syndrome, hyaline membrane disease, pneumonia, cystic fibrosis, idiopathic pulmonary fibrosis, atelectasis, and any combination thereof.
- In certain embodiments, the lung disease or lung condition is respiratory distress syndrome (RDS).
- In certain embodiments, the administering comprises liquid ventilation.
- In certain embodiments, the liquid ventilation is total liquid ventilation.
- In certain embodiments, the liquid ventilation is partial liquid ventilation.
- Compositions of the invention can be formulated for administration to lung. For example, a composition of the invention can be formulated with a pharmaceutically acceptable carrier, wherein the composition is provided in a therapeutically effective amount within a volume suitable for administration to an airway of a subject to be treated.
- As used herein, a “pharmaceutically acceptable carrier” refers to a biologically compatible aqueous fluid, e.g., water, normal saline, Ringer's solution, solution buffered to physiologic pH (pH 6.8-7.4).
- The pharmaceutically acceptable carrier can optionally include any one or more of salts, buffering agents, osmotically active agents, preservatives, and coloring agents, such as are well known in the pharmaceutical arts. See, e.g., Remington's The Science and Practice of Pharmacy, Lloyd V. Allen, Jr, editor, Philadelphia, Pa.: Pharmaceutical Press. 2012.
- For use in the lung, a suitable amount (volume) of composition of the invention so formulated can be instilled into an airway of the lung, e.g., via an endotracheal tube. Dosing may involve any one or combination of (i) lavage, (ii) partial liquid ventilation, and (iii) total liquid ventilation.
- Administration can be accomplished in a single dose or in multiple (i.e., two or more) doses. When the administration is accomplished in multiple doses, each dose can be the same, or at least one dose can differ from another dose.
- In certain embodiments, dosing can be based on corresponding surfactant alone.
- In certain embodiments, dosing can be based on corresponding PFC alone.
- In certain embodiments, the composition is administered once daily, twice daily, three times daily, four times daily, or more. In certain embodiments, the composition is administered every other day, every third day, every fourth day, every fifth day, every sixth day, or every seventh day.
- Generally, the administering physician or medical professional will be able to assess and adjust the dose and frequency of dosing based on such parameters as body weight, lung volumes, age, general medical condition, other medical conditions, and laboratory values such as O2 saturation, arterial blood gases (ABGs), and radiographic examination of the lungs.
- An aspect of the invention is a kit comprising silk fibroin in a first container and a perfluorocarbon in a second container. The kit may be conveniently presented with the components packaged together, for example in a box, tray, or foil pouch. The component silk fibroin and perfluorocarbon can be combined by an end user to make a composition in accordance with the invention.
- An aspect of the invention is a kit comprising silk fibroin in a first container and a surfactant in a second container. The kit may be conveniently presented with the components packaged together, for example in a box, tray, or foil pouch. The component silk fibroin and surfactant can be combined by an end user to make a composition in accordance with the invention.
- An aspect of the invention is a kit comprising silk fibroin in a first container, a perfluorocarbon in a second container, and a surfactant in a third container. The kit may be conveniently presented with the components packaged together, for example in a box, tray, or foil pouch. The component silk fibroin, perfluorocarbon, and surfactant can be combined by an end user to make a composition in accordance with the invention.
- Each of the foregoing kits can further include written instructions directing an end user how to assemble and/or administer the various components.
- Each of the foregoing kits can further include an applicator or other delivery device suitably constructed and arranged for use in administering the various and/or assembled components to a subject in need thereof. For example, in certain embodiments such applicator or delivery device can be a syringe.
- The invention may be further understood by reference to the following nonlimiting examples.
- Silk fibroin was obtained from Silk lab, Tufts Science and Technology Center, 4 Colby St Biomed Eng Dept., Medford, Mass.
- PFC was obtained from Origen Biomedical, Austin, Tex.
- Lung Surfactant called Infasurf was obtained from ONY, Inc. 1576 Sweet Home Road, Amherst, N.Y. 14228.
- Aqueous preparations of silk fibroin and perfluorocarbon (PFC); silk fibroin and surfactant; PFC and surfactant; and silk fibroin, PFC, and surfactant were prepared and visually inspected for homogeneity. Selected properties of silk fibroin and PFC are shown in Table 1. Selected properties of silk fibroin and surfactant are shown in Table 2. Representative results are shown in
FIGS. 1A-1E . -
TABLE 1 Selected properties of silk fibroin and PFC Property Silk Fibroin PFC Drug delivery effect + + pH 6-6.5 5-6 O2 permeability + +++ Biodegradability +++ +++ Biocompatibility +++ +++ Water solubility Yes No -
TABLE 2 Selected properties of silk fibroin and surfactant Property Silk Fibroin Surfactant Constituents protein and water protein and lipid Proteins Hydrophobic (HMW) Hydrophobic (BC+) Hydrophilic (LMW) Hydrophilic (A−) Surface Tension ?? Low (14-18 Dynes/cm) H2O: 70 Dynes/cm) Lung: 25 Dynes/cm pH 6-6.5 5.0-6.2 - Silk fibroin and surfactant formed a homogeneous mixture. Surfactant and PFC mixture was nonhomogeneous. Silk fibroin, PFC, and surfactant was homogeneous after vigorous shaking.
- A New Zealand white rabbit was used to test proof of concept. The animal weighing 1.58 kg anesthetized and after instrumentation, anesthesia was administered continuously as per protocol. The rabbit was intubated orally and ventilated on assist/control mode at 30 breaths/min, 0.4 fraction of inspired oxygen (FiO2), 0.35 sec inspiratory time, 4 cm H2O positive end expiratory pressure (PEEP), and tidal volume targeted to 7 mL/kg. The lungs were lavaged 4 times with 30 mL/kg of normal (0.9%) saline several times until blood gases were consistent with surfactant deficiency status. After a stabilization period of 30 min on the ventilator, arterial blood gas (ABG) analyses, mean arterial pressure (MAP), and arterial blood pressures were measured prior to administration of liquid fibroin and PFC 1:2 volume ratio (1 mL of silk fibroin to 2 mL of PFC). Oxygen saturations, arterial blood gases, and blood pressure were recorded at the end. Representative results are shown in Table 3.
-
TABLE 3 Effect of administration of silk fibroin/PFC to surfactant-deficient rabbit. Before After Parameter Fibroin/PFC Fibroin/PFC O2 saturation 85% 92% ABG 7.20/65/45/20/−9 7.31/55/60/23/−5 pH/PaCO2/PaO2/HCO3/base excess BP (mm Hg) 35/19 39/23 MAP (mm Hg) 24 28 - Administration of mixture of liquid silk fibroin and PFC to surfactant-deficient rabbit resulted in improvement in oxygen saturations and arterial blood gases and stabilization of mean blood pressure. Surfactant has already been shown to be effective in surfactant deficient-lung, strongly suggesting that inclusion of surfactant would only further improve results in this system.
- The observed improvement in blood gases and blood pressure after instillation of mixture of silk fibroin and PFC shows possible synergy between two liquids on surfactant-deficient lungs and suggests such mixture will have beneficial effect upon its addition to surfactant and administration to surfactant-deficient lungs.
- Rats, rabbits, or sheep are anesthetized, intubated, ventilated, and made surfactant-deficient in a manner similar to Example 2. Animals are then treated with test agent selected from (i) silk fibroin alone; (ii) PFC alone; (iii) surfactant alone; (iv) vehicle alone; (v) silk fibroin and PFC; (vi) silk fibroin and surfactant; (vii) PFC and surfactant; and/or (viii) silk fibroin, PFC, and surfactant by instillation into the lungs. Arterial blood gas (ABG), mean arterial pressure (MAP), and arterial blood pressures are measured prior to administration of test agent. Oxygen saturations, arterial blood gases, and blood pressures are recorded after administration of test agent. Comparison is made between pre- and post-administration clinical parameters. Results are expected to show that (viii) silk fibroin, PFC, and surfactant is superior to (i) silk fibroin alone; (ii) PFC alone; (iii) surfactant alone; (iv) vehicle alone; (v) silk fibroin and PFC; (vi) silk fibroin and surfactant; and (vii) PFC and surfactant, including synergistic improvement over (v) silk fibroin and PFC; (vi) silk fibroin and surfactant; and/or (vii) PFC and surfactant.
Claims (51)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/757,195 US20210121525A1 (en) | 2017-10-20 | 2018-10-19 | Silk fibroin-containing composition and methods of use thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762574993P | 2017-10-20 | 2017-10-20 | |
US16/757,195 US20210121525A1 (en) | 2017-10-20 | 2018-10-19 | Silk fibroin-containing composition and methods of use thereof |
PCT/US2018/056608 WO2019079661A1 (en) | 2017-10-20 | 2018-10-19 | Silk fibroin-containing composition and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210121525A1 true US20210121525A1 (en) | 2021-04-29 |
Family
ID=66173514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/757,195 Pending US20210121525A1 (en) | 2017-10-20 | 2018-10-19 | Silk fibroin-containing composition and methods of use thereof |
Country Status (2)
Country | Link |
---|---|
US (1) | US20210121525A1 (en) |
WO (1) | WO2019079661A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003277640A1 (en) * | 2002-11-11 | 2004-06-03 | Kowa Co., Ltd. | Composition for restoring damaged skin |
US9381273B2 (en) * | 2008-01-31 | 2016-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Scaffolds with oxygen carriers, and their use in tissue regeneration |
-
2018
- 2018-10-19 US US16/757,195 patent/US20210121525A1/en active Pending
- 2018-10-19 WO PCT/US2018/056608 patent/WO2019079661A1/en active Application Filing
Non-Patent Citations (2)
Title |
---|
Freire, Mara G. et al; "Solubility of water in fluyorocarbons: experimetnal and cosmo-rs prediction results." J. Chem. Thermodynamics (2010) 42 p213-219 * |
The Fischer scientific catalog page for perfluorooctyl bromide , https://www.fishersci.com/shop/products/perfluorooctyl-bromide-99-thermo-scientific/AC386790100, downloaded 1 May, 2023 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019079661A1 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8048043B2 (en) | Method of administration of a pulmonary surfactant | |
US20220040239A1 (en) | Therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving bpd | |
US20090170758A1 (en) | Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties | |
Perlman | The contribution of surface tension-dependent alveolar septal stress concentrations to ventilation-induced lung injury in the acute respiratory distress syndrome | |
US8357657B2 (en) | Therapeutic combination comprising a pulmonary surfactant and a steroid | |
US10124015B2 (en) | Surfactant composition | |
US20210121525A1 (en) | Silk fibroin-containing composition and methods of use thereof | |
Chess et al. | Surfactant replacement therapy in lung injury | |
JP4559731B2 (en) | New use of lung surfactant | |
US20240091319A1 (en) | Dual-administration methods for treating respiratory distress | |
Gardenhire | Surfactant Agents | |
Soll et al. | Surfactant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GEORGETOWN UNIVERSITY, DISTRICT OF COLUMBIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PEESAY, MORARJI;REEL/FRAME:055987/0492 Effective date: 20171222 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: GEORGETOWN UNIVERSITY, DISTRICT OF COLUMBIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PARANJAPE, MAKARAND;REEL/FRAME:059296/0529 Effective date: 20220302 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |